Merck, known as MSD outside the United States and Canada announced that the Food and Drug Administration (FDA) has approved two new HIV-1 medicines: Delstrigo and Pifeltro.
This fixed-dose tablet combines 600mg efavirenz, 200mg emtricitabine (FTC), and 245mg tenofovir disoproxil fumarate (TDF). Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback